Tigecycline in vitro activity against commonly encountered multidrug-resistant Gram-negative pathogens in a Middle Eastern country

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 4, 2008, Pages 411-415

  Araj, George F ^a   Ibrahim, Georges Y ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Lactamases; Multidrug resistant; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ACINETOBACTER; ARTICLE; CONTROLLED STUDY; DISK DIFFUSION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIDDLE EAST; NONHUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; LEBANON; MIDDLE AGED; MINOCYCLINE;

EID: 56049124086     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.08.011     Document Type: Article

References (37)

1. Araj G.F., and Kanj S.S. Current status and changing trends of antimicrobial resistance in Lebanon. Leb. Med. J. 48 (2000) 221-226
2. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., and Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41 (2005) S354-S367
3. Betriu C., Rodri{dotless}'guez-Avial L., Sánchez B.A., Gómez M., Álvarez J., Picazo J.J., and Spanish Group of Tigecycline. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46 (2000) 892-895
4. Biedenbach D.J., Beach M.L., and Jones R.N. In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 40 (2001) 173-177
5. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., and Dowzicky M.J. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial ( TEST Program; 2004). Diag. Microbiol. Infect. Dis. 52 (2005) 173-179
6. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., and Jones R.N. Antimicrobial activity of tigecycline and other broad spectrum antimicrobials tested against serine carbapenemase- and metallo-{beta}-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance program. Antimicrob. Agents Chemother. 52 (2008) 570-573
7. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement, M100-S16 (2006), CLSI, Wayne (PA)
8. Curcio D., and Fernandez F. Acinetobacter spp. Susceptibility to tigecycline: a worldwide perspective. J Antimicrob Chemother 60 (2007) 449-450
9. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41 (2005) S341-S353
10. Fraise A.P. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?. J. Infect. 53 (2006) 293-300
11. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 195-201
12. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36 (2000) 19-36
13. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., and Dowzicky M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 215-227
14. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., and Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 45 (2007) 227-230
15. Kanafani Z.A., Mehio-Sibai A., Araj G.F., Kanaan M., and Kanj S.S. Epidemiology and risk factors for extended-spectrum beta-lactamase producing organisms: a case control study at a tertiary care center in Lebanon. Am. J. Infect. Control 33 (2005) 326-332
16. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., and Franklin C. Antibiogram of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. CID 45 (2007) 594-598
17. Livermore D.M. Tigecycline: what is it, and where should it be used?. J. Antimicrob. Chemother. 56 (2005) 611-614
18. Milatovic D., Schmitz F.J., Verhoef J., and Fluit A.C. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47 (2003) 400-404
19. Murray P.R., Baron E.J., Jorgensen J.H., Pfaller M.A., and Yolken R.H. Manual of Clinical Microbiology. 8th ed. (2003), American Society for Microbiology, Washington, DC
20. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., and Quinn J.P. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289 (2003) 885-888
21. Noskin G.A. Tigecycline; a new glyclycline for treatment of serious infections. CID 41 (2005) S303-S314
22. Pachon-Ibanez M.E., Jimenez-Mejias M.E., Pichardo C., Llaanos A.C., and Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother. 48 (2004) 4479-4481
23. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., and Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. (2007) 3471-3484
24. Reid G.E., Grim S.A., Aldeza C.A., Janda W.M., and Clark N.M. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27 (2007) 1198-1201
25. Reynolds R., Potz N., Colman M., Williams A., Livermore D., MacGowan A., and on behalf of the BSAC Extended Working group on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC bacteraemia resistance surveillance programme. J Antimicrob Chemother 53 (2004) 1018-1032
26. Sader H.S., Jones R.N., Stiwell M.G., Dowzicky M.J., and Fritsche T.R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52 (2005) 181-186
27. Schafer J.J., Goff D.A., Stevenson K.B., and Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27 (2007) 980-987
28. Samaha-Kfoury J.N., and Araj G.F. Recent developments in β-lactamases and extended spectrum β-lactamases. BMJ 327 (2003) 1209-1213
29. Samaha-Kfoury J., Kanj S.S., and Araj G.F. In vitro activity of antimicrobial agents against extended-spectrum B-lactamase producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Am. J. Infect. Control. 33 (2005) 134-136
30. Stein G.E., and Craig W.A. Tigecycline: a critical analysis. CID 43 (2006) 518-524
31. Tan T.Y., and Ng L.S.Y. Susceptibility of multi-resistant gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann. Acad. Med. Singapore 36 (2007) 807-810
32. Tiengrim S., Tribuddharat C., and Thamlikitkul V. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. J. Med. Assoc. Thai. 89 Suppl. 5 (2006) S102-S105
33. Vouillamoz J Moreillon P., Giddey M., and Entenza J.M. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J. Antimicrob. Chemother. 61 (2008) 371-374
34. Waites K.B., Duffy L.B., and Dowzicky M.J. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob. Agents Chemother. 50 (2006) 3479-3484
35. Wyeth Pharmaceuticals. Tigacil (tigecycline) product insert (2005), Wyeth Pharmaceuticals, Philadelphia, PA. http://www.tygacil.com [online]
36. Zhang Y.Y., Zhou L., Zhu D.M., Wu P.C., Hu F.P., Wu W.H., and Wang F. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn. Microbiol. Infect. Dis. 50 (2004) 267-281
37. Zinner S.H. Overview of antibiotic use and resistance: setting the stage for tigecycline. CID 41 (2005) S289-S292